Urovant Sciences

General Information


We are a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions. Our product candidate, vibegron, is an oral, once-daily, small molecule that, based on in vitro data, is a potent and highly selective beta-3 agonist. We are currently evaluating vibegron in our 1,400 patient, international pivotal Phase 3 clinical trial for the treatment of overactive bladder, or OAB. We expect to report top-line results from this clinical trial in the first or second quarter of 2019, and if the results are positive, we plan to submit a new drug application to the U.S. Food and Drug Administration, or FDA, by early 2020.


Employees: 0
Founded: 2016
Contact Information
Address Suite 1, 3rd Floor, 11-12 St. James’s Square, London SW1Y 4LB, United Kingdom
Phone Number +44 203 318 9709
Web Address http://www.urovant.com
View Prospectus: Urovant Sciences
Financial Information
Market Cap $420.4mil
Revenues $0 mil (last 12 months)
Net Income $-64.8 mil (last 12 months)
IPO Profile
Symbol UROV
Exchange NASDAQ
Shares (millions): 10.0
Price range $14.00 - $14.00
Est. $ Volume $140.0 mil
Manager / Joint Managers J.P. Morgan/ Jefferies/ Cowen
CO-Managers -
Expected To Trade: 9/27/2018
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change